The clinical utility of aflibercept for diabetic macular edema

References

• KleinRRetinopathy in a population-based studyTrans Am Ophthalmol Soc199290561 5941494834
   PubMedGoogle Scholar
• KleinBEKOverview of epidemiologic studies of diabetic retinopathyOphthalmic Epidemiol2007144179 18317896294
   PubMed Web of Science ®Google Scholar
• PascoliniDMariottiSPGlobal estimates of visual impairment: 2010Br J Ophthalmol2012965614 61822133988
   PubMed Web of Science ®Google Scholar
• FrankRNDiabetic retinopathyN Engl J Med2004350148 5814702427
   PubMed Web of Science ®Google Scholar
• DingJWongTYCurrent epidemiology of diabetic retinopathy and diabetic macular edemaCurr Diab Rep2012124346 35422585044
   PubMed Web of Science ®Google Scholar
• VarmaRBresslerNMDoanQVPrevalence and risk factors for diabetic macular edema in the United StatesJAMA Ophthalmol20141321334 134025125075
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSEDavisMDDeMetsDLThe Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edemaOphthalmology198491121464 14746521986
   PubMed Web of Science ®Google Scholar
• WilliamsRAireyMBaxterHForresterJKennedy-MartinTGirachAEpidemiology of diabetic macular oedema: a systematic reviewEye20041810963 98315232600
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSECruickshanksMJThe Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edemaOphthalmology19951027 167831044
   PubMed Web of Science ®Google Scholar
• TranosPGWickremasingheSSStangosNTTopouzisFTsinopoulosIPavesioCEMacular edemaSurv Ophthalmol2004495470 49015325193
   PubMed Web of Science ®Google Scholar
• ShamoonHDuffyHFleisherNThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med199332914977 9868366922
   PubMed Web of Science ®Google Scholar
• Lopes de FariaJMJalkhAETrempeCLMcMeelNWDiabetic macular edema: risk factors and concomitantsActa Ophthalmol Scand1999772170 17510321533
   PubMedGoogle Scholar
• BenarousRSasongkoMBQureshiSDifferential association of serum lipids with diabetic retinopathy and diabetic macular edemaInvest Ophthalmol Vis Sci201152107464 746921862642
   PubMed Web of Science ®Google Scholar
• LimLSWongTYLipids and diabetic retinopathyExpert Opin Biol Ther201212193 10522122357
   PubMed Web of Science ®Google Scholar
• BlochSBLarsenMMunchICIncidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010Am J Ophthalmol20121532209 21322264944
   PubMed Web of Science ®Google Scholar
• KingHAubertREHermanWHGlobal burden of diabetes, 1995–2025: prevalence, numerical estimates, and projectionsDiabetes Care1998211414 14319727886
   PubMed Web of Science ®Google Scholar
• AntonettiDAKleinRGardnerTWDiabetic retinopathyN Engl J Med20123661227 123922455417
   PubMed Web of Science ®Google Scholar
• MitchellPWongTYfor the Diabetic Macular Edema Treatment Guideline Working GroupManagement paradigms for diabetic macular edemaAm J Ophthalmol2014157505 51324269850
   PubMed Web of Science ®Google Scholar
• OlsonJSharpPGoatmanKImproving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicenter, UK studyHealth Technol Assess201317511 14224225334
   PubMed Web of Science ®Google Scholar
• VirgiliGParravanoMMenchiniFEvansJRAnti-vascular endothelial growth factor for diabetic macular oedemaCochrane Database Syst Rev201410CD00741925342124
   PubMed Web of Science ®Google Scholar
• KaiserPKVascular endothelial growth factor Trap-eye for diabetic macular edemaBr J Ophthalmol2009932135 13619174397
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study GroupPhotocoagulation for diabetic macular edema. ETDRS report no 4Int Ophthalmol Clin198727265 2723692708
   PubMedGoogle Scholar
• Early Treatment Diabetic Retinopathy Study GroupPhotocoagulation for diabetic macular edema. ETDRS report no 1Arch Ophthalmol19851031644 16522865943
   PubMedGoogle Scholar
• Diabetic Retinopathy Clinical Research NetworkA randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edemaOphthalmology20081151447 144918662829
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDShahSMAn exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-eye in patients with diabetic macular oedemaBr J Ophthalmol200993144 14919174400
   PubMed Web of Science ®Google Scholar
• PournarasCJTsacopoulosMStrommerKScatter photocoagulation restores tissue hypoxia in experimental vasoproliferative microangiopathy in miniature pigsOphthalmology1990971329 13332243683
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMVan AndenESupplemental inspired oxygen improves diabetic macular edema; a pilot studyInvest Ophthalmol Vis Sci200345617 62414744906
   PubMed Web of Science ®Google Scholar
• LuttrullJIDorinGSubthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a reviewCurr Diabetes Rev201284274 28422587512
   PubMedGoogle Scholar
• Do carmoARamosPReisABreakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetesExp Eye Res199867569 5759878219
   PubMed Web of Science ®Google Scholar
• OzakiHHayashiHVinoresSAIntravitreal sustained release of VEGF causes retinal neovascularization in rabbits and primatesExp Eye Res199764505 5179227268
   PubMed Web of Science ®Google Scholar
• MichaelsonICVascular morphogenesis in the retina of the catJ Anat194882Pt 3167 174
   Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med1971285211182 11864938153
   PubMed Web of Science ®Google Scholar
• SengerDRGalliSJDvorakAMPerruzziCAHarveyVSDvorakHFTumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluidScience198312983 9856823562
   PubMed Web of Science ®Google Scholar
• FerraraNHenzelWJPituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochem Biophys Res Commun1989161851 8582735925
   PubMed Web of Science ®Google Scholar
• ConnollyDTHeuvelmanDMNelsonRTumor vascular permeability factor stimulates endothelial cell growth and angiogenesisJ Clin Invest1989841470 14782478587
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factorArterioscler Thromb Vasc Biol200929789 79119164810
   PubMed Web of Science ®Google Scholar
• HouckKAFerraraNWinerJCachianesGLiBLeungDWThe vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNAMol Endocrinol199151806 18141791831
   PubMed Web of Science ®Google Scholar
• TischerEMitchellRHartmanTThe human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicingJ Biol Chem199126611947 119541711045
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039669 67612778165
   PubMed Web of Science ®Google Scholar
• MaxwellPHRatcliffePJOxygen sensors and angiogenesisSemin Cell Dev Biol20021329 3711969369
   PubMed Web of Science ®Google Scholar
• RobbinsSGConawayJRFordBLRobertoKAPennJSDetection of vascular endothelial growth factor (VEGF) protein in vascular and non-vascular cells of the normal and oxygen-injured rat retinaGrowth Factors1997144229 2419386988
   PubMed Web of Science ®Google Scholar
• NomuraMYamagishiSHaradaSPossible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytesJ Biol Chem199527028316 283247499331
   PubMed Web of Science ®Google Scholar
• NishikioriNOsanaiMChibaHGlial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathyDiabetes2007561333 134017470563
   PubMed Web of Science ®Google Scholar
• DeisslerHLDeisslerHLangGKLangGEVEGF but not PlGF disturbs the barrier of retinal endothelial cellsExp Eye Res2013115162 17123891860
   PubMed Web of Science ®Google Scholar
• JonasJBJonasRANeumaierMFindeisenPCytokine concentration in aqueous humor of eyes with diabetic macular edemaRetina201232102150 215722617833
   PubMed Web of Science ®Google Scholar
• KowalczukLTouchardEOmriSPlacental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathyPLos One201163e1746221408222
   PubMed Web of Science ®Google Scholar
• HuangHHeJJohnsonDDeletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibitionDiabetes201564200 21225187372
   PubMed Web of Science ®Google Scholar
• TolentinoMJMillerJWGragoudasESIntravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primateOphthalmology19961031820 18288942877
   PubMed Web of Science ®Google Scholar
• TolentinoMJMcLeodDSTaomotoMPathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primateAm J Ophthalmol2002133373 38511860975
   PubMed Web of Science ®Google Scholar
• AdamisAPMillerJWBernalMTIncreased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathyAm J Ophthalmol1994118445 4507943121
   PubMed Web of Science ®Google Scholar
• FunatsuHYamashitaHNomaHIncreased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edemaAm J Ophthalmol200213370 7711755841
   PubMed Web of Science ®Google Scholar
• CunninghamETAdamisAPAltaweelMA phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edemaOphthalmology20051121747 175716154196
   PubMed Web of Science ®Google Scholar
• RajendramRFraser-BellSKainesAA 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3Arch Ophthalmol2012130972 97922491395
   PubMed Web of Science ®Google Scholar
• NguyenQDTatlipinarSShahSMVascular endothelial growth factor is critical stimulus for diabetic macular edemaAm J Ophthalmol2006142961 96917046701
   PubMed Web of Science ®Google Scholar
• ChunDWHeierJSToppingTMDukerJSBankertJMA pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edemaOphthalmology20061131706 171217011952
   PubMed Web of Science ®Google Scholar
• MassinPBandelloFGarwegJGSafety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II studyDiabetes Care2010332399 240520980427
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMHeierJSPrimary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology20091162175 218119700194
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology20101172146 215120855114
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDKhwajaAAfor the READ-2 Study GroupRanibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatmentJAMA Ophthalmol20131312139 14523544200
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloUSchmidt-ErfurthUThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology20111184615 62521459215
   PubMed Web of Science ®Google Scholar
• NguyenQDBrownDMMarcusDMRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology20121194789 80122330964
   PubMed Web of Science ®Google Scholar
• BrownDMNguyenQDMarcusDMLong-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDEOphthalmology2013120102013 202223706949
   PubMed Web of Science ®Google Scholar
• ElmanMJAielloLPBeckRWRandomized trial evaluating ranibizumab plus prompt laser for diabetic macular edemaOphthalmology201011761064 107720427088
   PubMed Web of Science ®Google Scholar
• ElmanMJQinHAielloLPIntravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial resultsOphthalmology2012119112312 231822999634
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadoupoulosNVEGF-Trap: a VEGF blocker with potent anti-tumor effectsProc Natl Acad Sci U S A20029911393 1139812177445
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215171 18522302382
   PubMed Web of Science ®Google Scholar
• RudgeJSHolashJHyltonDVEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockadeProc Natl Acad Sci U S A200710418363 1837018000042
   PubMed Web of Science ®Google Scholar
• FurfineECoppiAKoehler-StecEZimmerETuWStrubleCPharmacokinetics and ocular tissue penetration of VEGF Trap after intravitreal injections in rabbitsInvest Ophthalmol Vis Sci200847 E-abstract 1430
   Google Scholar
• BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology20071142179 218218054637
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSSinghRJPharmacokinetics of intravitreal bevacizumab (Avastin)Ophthalmology2007114855 85917467524
   PubMed Web of Science ®Google Scholar
• StewartMWWhat are the half-lives of ranibizumab, aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical modelEye Rep20111112 14
   Google Scholar
• AveryRCastellarinAASteinleNCSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDBr J Ophthalmol201498121636 164125001321
   PubMed Web of Science ®Google Scholar
• DoDVSchmidt-UrfurthUGonzalezVHThe DA VINCI Study: phase 2 primary results of VEGF Trap-eye in patients with diabetic macular edemaOphthalmology20111181819 182621546089
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDBoyerDOne-year outcomes of the DA VINCI study of VEGF Trap-eye in eyes with diabetic macular edemaOphthalmology20121191658 166522537617
   PubMed Web of Science ®Google Scholar
• KorobelnikJ-FDoDVSchmidt-UrfurthUIntravitreal aflibercept for diabetic macular edemaOphthalmology20141212247 225425012934
   PubMed Web of Science ®Google Scholar
• RégnierSMalcolmWAllenFWrightJBezlyakVEfficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systemic review and network meta-analysisPLoS One201497e10230925029255
   PubMed Web of Science ®Google Scholar
• WellsJAGlassmanARAyalaARfor the Diabetic Retinopathy Research networkAflibercept, bevacizumab, or ranibizumab for diabetic macular edemaN Engl J Med2015372131193 120325692915
   PubMed Web of Science ®Google Scholar
• SmiddyWEClinical applications of cost analysis of diabetic macular treatmentsOphthalmology20121192558 256223062655
   PubMed Web of Science ®Google Scholar